--- title: Generate Biomedicines Sets Terms for $400 Million IPO as Asthma-Focused AI Biotech Advances Generative Protein Platform description: A clinical-stage generative biology company integrating machine learning with protein engineering seeks to fund late-stage asthma development and expand its AI-driven discovery engine. image: https://blog.ipoprophet.com/hubfs/Generate%20Biosciences%20Image.png --- [Skip to content](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform#main-content) [![IPO_PROPHET_BLUE logo](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_BLUE%20logo.png?width=2973&height=302&name=IPO_PROPHET_BLUE%20logo.png)](https://www.IPOProphet.com) - [Login](https://app.ipoprophet.com/login) Open main navigation Close main navigation - [Login](https://app.ipoprophet.com/login) [Subscribe to our Newsletter](https://share.hsforms.com/1xXldKrGiQBCbNmtOz6j4Jwq3cu4) [Go Back to Home](http://www.ipoprophet.com/) [Go Back to Blog](http://www.ipoprophet.com/blog) Feb 23, 2026 4:06:42 PM # Generate Biomedicines Sets Terms for $400 Million IPO as Asthma-Focused AI Biotech Advances Generative Protein Platform ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Share: [facebook-f icon](http://www.facebook.com/share.php?u=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform) [Twitter icon](https://twitter.com/intent/tweet?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform) [envelope icon](mailto:?body=https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform) ![](https://blog.ipoprophet.com/hs-fs/hubfs/image-png-Feb-23-2026-08-55-48-8407-PM.png?width=524&height=143&name=image-png-Feb-23-2026-08-55-48-8407-PM.png)   **Generate Biomedicines** has set terms for its initial public offering, seeking to raise approximately **$400 million** by offering **25,000,000 shares** at a price range of **$15.00 to $17.00 per share** (Generate Biomedicines S-1\_A). At the **$16.00 midpoint**, the company would raise roughly **$400 million** in gross proceeds and debut with an implied post-IPO market capitalization of approximately **$1.6 billion**, excluding any underwriters’ option. The company plans to list on the Nasdaq under the ticker **GENB**, with **Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor** leading the offering. Founded in 2018 and headquartered in Somerville, Massachusetts (Generate Biomedicines S-1\_A), Generate is building a generative biology platform that applies machine learning to design novel protein therapeutics. By combining computational modeling with laboratory validation, the company aims to engineer biologics with defined structure and function, potentially accelerating discovery timelines and expanding druggable targets.   ![](https://blog.ipoprophet.com/hs-fs/hubfs/image-png-Feb-23-2026-08-58-02-9977-PM.png?width=742&height=273&name=image-png-Feb-23-2026-08-58-02-9977-PM.png)   The pipeline includes a long-acting antibody candidate targeting severe asthma, a large biologics market where durability and dosing profile remain key competitive factors. Beyond its internal programs, Generate has secured strategic collaborations with major pharmaceutical companies, including six confidential programs with **Amgen** announced in 2022 and multiple confidential programs with **Novartis** announced in 2024 (Generate Biomedicines S-1\_A). These partnerships provide platform validation and contribute collaboration revenue while allowing the company to retain wholly owned development assets. ![](https://blog.ipoprophet.com/hs-fs/hubfs/image-png-Feb-23-2026-08-57-17-7553-PM.png?width=765&height=278&name=image-png-Feb-23-2026-08-57-17-7553-PM.png)   Financially, Generate remains a development-stage biotech. Collaboration revenue increased to $31.9 million in FY 2025 from $20.5 million in FY 2024, while research and development expenses rose to $224.7 million from $175.3 million as pipeline investment accelerated. Net loss widened to $203.2 million in FY 2025 compared to $173.8 million the prior year, reflecting continued clinical advancement.   ![](https://blog.ipoprophet.com/hs-fs/hubfs/image-png-Feb-23-2026-08-56-22-2727-PM.png?width=771&height=515&name=image-png-Feb-23-2026-08-56-22-2727-PM.png)   The IPO comes amid renewed enthusiasm for artificial intelligence across sectors, though biotech investors remain focused on clinical validation and capital discipline. Generate’s positioning blends AI momentum with a tangible asthma program and pharmaceutical partnerships. The bull case hinges on platform scalability and successful clinical differentiation; the bear case centers on execution risk and the reality that AI-enabled discovery must ultimately prove itself through data. With a proposed $400 million raise and meaningful big pharma collaborations in place, Generate Biomedicines enters the public markets as a platform-driven biotech seeking to translate computational design into clinical proof and long-term therapeutic value. Generate Biomedicines is expected to trade Friday, February 27th, 2026.   [Nasdaq](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/nasdaq), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Generate Biomedicines](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/generate-biomedicines) ## Related posts [![](https://blog.ipoprophet.com/hs-fs/hubfs/Fervo%20Energy%20Thumbnail.png?height=200&name=Fervo%20Energy%20Thumbnail.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/fervo-energy-frvo-sets-terms-for-blockbuster-ipo-as-enhanced-geothermal-pioneer-scales-next-generation-baseload-power) [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [Nasdaq](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/nasdaq), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [Fervo Energy](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/fervo-energy) ## [Fervo Energy (FRVO) Sets Terms for  Blockbuster IPO as Enhanced Geothermal Pioneer Scales Next-Generation Baseload Power](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/fervo-energy-frvo-sets-terms-for-blockbuster-ipo-as-enhanced-geothermal-pioneer-scales-next-generation-baseload-power) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) May 8, 2026 2:50:44 PM [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/fervo-energy-frvo-sets-terms-for-blockbuster-ipo-as-enhanced-geothermal-pioneer-scales-next-generation-baseload-power) [![](https://blog.ipoprophet.com/hs-fs/hubfs/SpyGlass%20Thumbnail.png?height=200&name=SpyGlass%20Thumbnail.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/spyglass-pharma-sets-terms-for-ipo-as-ophthalmology-focused-biotech-advances-sustained-release-platform) [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [Nasdaq](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/nasdaq), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [SpyGlass Pharma](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/spyglass-pharma) ## [SpyGlass Pharma Sets Terms for IPO as Ophthalmology-Focused Biotech Advances Sustained-Release Platform](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/spyglass-pharma-sets-terms-for-ipo-as-ophthalmology-focused-biotech-advances-sustained-release-platform) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Jan 30, 2026 4:51:35 PM [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/spyglass-pharma-sets-terms-for-ipo-as-ophthalmology-focused-biotech-advances-sustained-release-platform) [![](https://blog.ipoprophet.com/hs-fs/hubfs/Agomab%20Thumbnail.png?height=200&name=Agomab%20Thumbnail.png)](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/agomab-therapeutics-sets-terms-for-ipo-as-fibrosis-focused-biotech-advances-clinical-pipeline) [IPOs](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/ipos), [Nasdaq](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/nasdaq), [2026](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/2026), [AgomAb](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/tag/agomab) ## [AgomAb Therapeutics Sets Terms for IPO as Fibrosis-Focused Biotech Advances Clinical Pipeline](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/agomab-therapeutics-sets-terms-for-ipo-as-fibrosis-focused-biotech-advances-clinical-pipeline) ![Picture of Eric Friedman](https://app.hubspot.com/settings/avatar/7a4cca62b5a89282b41a283a43efa80e) [Eric Friedman](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman) Jan 30, 2026 2:56:35 PM AgomAb Therapeutics NV has set terms for its initial public offering, positioning the... [Read more](https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/agomab-therapeutics-sets-terms-for-ipo-as-fibrosis-focused-biotech-advances-clinical-pipeline) [linkedin-in icon](https://www.linkedin.com/company/ipo-prophet-software/) [X Twitter icon](https://www.x.com/ipoprophet) --- [![IPO_PROPHET_WHITE-2](https://blog.ipoprophet.com/hs-fs/hubfs/IPO_PROPHET_WHITE-2.png?width=800&height=250&name=IPO_PROPHET_WHITE-2.png "IPO_PROPHET_WHITE-2")](http://www.ipoprophet.com) NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE. Copyright © 2025 ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Eric Friedman", "url" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/author/eric-friedman" }, "dateModified" : "2026-02-23T21:06:42.749Z", "datePublished" : "2026-02-23T21:06:42.000Z", "headline" : "Generate Biomedicines Sets Terms for $400 Million IPO as Asthma-Focused AI Biotech Advances Generative Protein Platform", "image" : [ "https://blog.ipoprophet.com/hubfs/Generate%20Biosciences%20Image.png" ], "mainEntityOfPage" : { "@id" : "https://blog.ipoprophet.com/aslgkuh89gyaep98byanp9t8yaqtp98hyq358yna8pq48y/generate-biomedicines-sets-terms-for-400-million-ipo-as-asthma-focused-ai-biotech-advances-generative-protein-platform", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.ipoprophet.com/hubfs/IPO_PROPHET_BLUE%20logo-1.png" }, "name" : "ipoprophet.com" } } ```